ReNAgade Emerges With $300m To Pursue Extra-Hepatic Delivery Of RNA Medicines
New CEO Amit Munshi Last Helmed Arena
Executive Summary
ReNAgade Therapeutics came out of stealth mode with $300m to fund its proprietary technology for delivery of RNA medicines – including coding, editing and gene insertion modalities – beyond the liver.
You may also be interested in...
The Biopharma A List: Taking The Pulse Of Newco Creation
On the new company creation front, using Series A financings as a proxy, start-ups have not escaped the challenging funding environment. Here we update trends in those first-time rounds for 2023.
BIO Notebook Day 3: Venture Capital Musical Chairs, Pfizer’s Financing Strategy, And Boehringer on Being The Early Bird
Plus, Roche talks about why it wants to partner with firms that have machine learning expertise as the BIO International Convention continues in Boston.
BIO Notebook: Venture Capital Musical Chairs, Pfizer’s Financing Strategy, And Boehringer on Being The Early Bird
Plus, Roche talks about why it wants to partner with firms that have machine learning expertise as the BIO International Convention continues in Boston.